Exchange of missile strikes between Israel and Iran threatens fragile ceasefire Ivar AI

Crypto Briefing

US military strikes Iranian radar sites after drone launch, and crypto markets are bracing for impact

Crypto Briefing

US military launches airstrikes against Iran after helicopter downing near Strait of Hormuz

PRNewswire

Oracle Announces Record Q4 and FY 2026 Results Driven by Cloud Infrastructure & Cloud Applications

Yahoo Entertainment

幫馬斯克撈火箭！27歲的她有望變億萬富豪　靠「1大膽決定」迎SpaceX上市

PRNewswire

Flex to Join S&P 500 Index

Crypto Briefing

House passes sanctions on Russia and aid for Ukraine amid Senate uncertainty

tagesschau.de

US-Armee meldet Angriffe auf Iran nach Vorwurf des Helikopter-Abschusses

Macdailynews.com

Apple’s iPhone momentum shines bright: 19.7% YoY production surge positions it for market leadership amid industry headwinds

Noticiabrasil.net.br

A nova fronteira do agro: como o Brasil pode liderar IA para agricultura?

CBS News

U.S. targets Iran's ammunition depots, more in new wave of strikes

GlobeNewswire

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

PBS

U.S. launches new strikes in Iran after missiles target American bases

Crypto Briefing

Cynthia Lummis calls for US to accumulate Bitcoin openly while other nations buy quietly

Www.abc.es

EE.UU. ataca Irán «en legítima defensa» por el «derribo» de un helicóptero en Ormuz

Crypto Briefing

Middle East oil output slashed by 11M bpd amid Strait of Hormuz blockade: EIA

SiliconANGLE News

Neura Robotics to raise up to $1.4B from Nvidia-backed consortium

Crypto Briefing

NYSE reports 50% revenue growth and 10x increase in free cash flow

36kr.com

SpaceX获得三大债券评级机构的投资级评级

$Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire$

GlobeNewswire

Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire